News | November 01, 2024
Merck and Moderna initiate Phase 3 trial evaluating adjuvant V940 in combination with Keytruda
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
The Shasta system and Shasta Whole-Genome Amplification (WGA) Kit dramatically increase throughput for WGA by processing up to 1,500 cells per run
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and older
Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes
Subscribe To Our Newsletter & Stay Updated
